Esophageal Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Esophageal cancer encompasses two principal histological types with distinct epidemiology, risk factors, and treatment approaches. Squamous cell carcinoma (SCC) arises from the squamous epithelium of the upper and mid esophagus, linked to tobacco, heavy alcohol use, and hot beverage consumption; it predominates globally, particularly in East Africa, Iran, and China. Adenocarcinoma arises predominantly from Barrett's esophagus — a metaplastic change from chronic gastroesophageal reflux disease (GERD) — in the lower esophagus and gastroesophageal junction (GEJ); it has increased in incidence 6-fold in Western countries over the past four decades and is now the dominant subtype in the US and Europe. Approximately 22,000 new US cases occur annually, with an estimated 16,000 deaths, reflecting the dismal prognosis associated with late-stage presentation: over 70% of patients present with locally advanced or metastatic disease.

Esophageal SCC risk factors include heavy tobacco smoking, alcohol consumption (with a multiplicative synergistic risk when combined), very hot beverage consumption (associated with SCC in high-incidence regions), achalasia, caustic injury strictures, prior head and neck cancer (field cancerization), nutritional deficiencies (riboflavin, vitamin A, zinc, selenium), and nitrosamine exposure from dietary sources. Adenocarcinoma risk factors include chronic GERD (reflux esophagitis progressing to Barrett's metaplasia), obesity (visceral adiposity increases reflux pressure and intra-abdominal pressure), and a diet low in fruits and vegetables. Male sex increases adenocarcinoma risk 4–7-fold compared to females. HER2 amplification occurs in approximately 15–20% of GEJ adenocarcinomas and is an actionable therapeutic target. PD-L1 CPS expression guides immunotherapy selection for both histological types.

Progressive dysphagia — initially to solid foods and advancing over weeks to semisolids and then liquids as the tumor narrows the esophageal lumen — is the cardinal symptom of esophageal cancer, occurring in approximately 90% of patients at presentation. Odynophagia (painful swallowing) indicates ulceration or periesophageal extension. Significant weight loss (often 10–20 lbs before diagnosis) results from both dysphagia-related reduced intake and tumor-related systemic inflammation. Hoarseness indicates invasion of the left recurrent laryngeal nerve. Chronic cough, aspiration, or new tracheoesophageal fistula manifesting as paroxysmal coughing with liquid intake indicates tracheobronchial invasion. Hematemesis or melena indicates tumor ulceration. Back pain suggests mediastinal or vertebral involvement.

Upper GI endoscopy (EGD) with biopsy establishes the histological diagnosis. Endoscopic ultrasound (EUS) is the most accurate modality for T (tumor depth) and N (regional nodal) staging, enabling distinction of T1–T4 invasion depth and evaluation of peritumoral lymph nodes with EUS-guided fine needle aspiration. CT of the chest, abdomen, and pelvis identifies regional lymphadenopathy and distant metastases. PET-CT improves detection of occult nodal disease and distant metastases and is recommended for potentially curable disease. Laparoscopy excludes peritoneal dissemination in GEJ adenocarcinoma. HER2 amplification testing (IHC and FISH) is performed for all GEJ and gastric adenocarcinomas. PD-L1 combined positive score (CPS) guides immunotherapy eligibility. AJCC 8th edition TNM staging (clinical and pathological) with separate classifications for SCC and adenocarcinoma drives treatment decisions.

Treatment is stage-dependent and histotype-informed. Early-stage (T1a) disease: endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for T1a tumors. Resectable stage I–III adenocarcinoma: perioperative FLOT chemotherapy (4 cycles before and 4 cycles after surgery), as established by the FLOT4 trial, is the current European standard; North American practice uses CROSS neoadjuvant chemoradiation (carboplatin/paclitaxel + 41.4 Gy) followed by transthoracic Ivor Lewis esophagectomy. Resectable SCC: CROSS protocol (achieves 49% pCR in SCC vs 23% in adenocarcinoma) or definitive chemoradiation for patients refusing or unfit for surgery. Adjuvant nivolumab for 1 year after CROSS plus esophagectomy improves DFS (CheckMate 577). Metastatic SCC: nivolumab plus chemotherapy (CheckMate 648) or pembrolizumab (KEYNOTE-590) first-line. HER2-positive GEJ adenocarcinoma: trastuzumab plus chemotherapy. Pembrolizumab plus platinum-5FU for CPS ≥10 first-line adenocarcinoma.

Five-year overall survival remains approximately 20% for all stages combined. Localized esophageal cancer: 5-year survival approximately 47%; regional disease: approximately 25%; distant metastases: approximately 5%. The FLOT4 trial improved median OS for resectable GEJ/gastric adenocarcinoma to 50 months versus 35 months with ECF. Perioperative CROSS achieved median OS of 48.6 months versus 24 months in surgery alone. Nivolumab in CheckMate 648 improved OS for advanced SCC to 15.4 months versus 9.1 months. Pathological complete response (pCR) after neoadjuvant therapy confers substantially improved survival. The prognosis for Esophageal Cancer: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

Tobacco cessation and alcohol reduction significantly reduce esophageal SCC risk — risk declines within 5 years of cessation. Barrett's esophagus surveillance is the primary prevention strategy for adenocarcinoma: patients with long-segment Barrett's (≥3 cm) undergo upper endoscopy with 4-quadrant biopsies every 3–5 years. Low-grade dysplastic Barrett's is treated with radiofrequency ablation (RFA) to reduce progression to adenocarcinoma. High-grade dysplasia warrants endoscopic eradication. Weight management and treatment of GERD with proton pump inhibitors reduce Barrett's progression risk. Avoid consistently drinking very hot beverages to reduce SCC risk. Daily aspirin may reduce adenocarcinoma risk in Barrett's patients but must be balanced against bleeding risk.

Seek prompt medical evaluation for progressive difficulty swallowing, especially if it began with solid foods and is worsening. Do not attribute new-onset dysphagia to aging or stress — it requires endoscopy. Sudden ability to swallow again after a period of dysphagia may indicate tumor ulceration with luminal widening and should still be investigated. Unexplained weight loss, persistent heartburn unresponsive to antacids, or new-onset persistent hoarseness or cough in a smoker or heavy drinker requires urgent evaluation. Any patient with known Barrett's esophagus should adhere to scheduled endoscopic surveillance and notify their gastroenterologist promptly if new symptoms develop. Hematemesis, blood-streaked vomiting, black tarry stools, or severe chest or back pain require emergency evaluation.